Le Lézard
Classified in: Health
Subjects: NPT, AVO, MAT

Medical Board of California Allows Doctor Responsible for the Death and Injury of Eight Bakersfield Patients to Keep Medical License, Says Consumer Watchdog


BAKERSFIELD, Calif., June 3, 2020 /PRNewswire/ -- The Medical Board of California's decision to allow Dr. Arthur Park to continue practicing, despite a 20-year track record of negligence causing catastrophic injuries and death in the Bakersfield community, will unconscionably place even more patients at risk, said Consumer Watchdog today. The Medical Board signed a settlement deal with Dr. Park last week which has granted him five years of probation and the ability to continue to practice with restrictions.

The settlement involved the death of a 23-year-old woman. This 23-year-old mother successfully delivered her child and yet bled to death while under the care of Dr Park. Without consent or any medical reason, Dr. Park forcibly removed her placenta with forceps, by hand, and again with forceps until he tore the placenta from her womb as she screamed in agonizing pain.

According to the Coroner's report, he traumatically perforated her uterus and cervix causing her to hemorrhage. Dr. Park continuously ignored prompting from nurses to help his patient, not offering her medical care as her vitals plummeted and she bled to death.

Dr. Park was previously on probation for three years for his negligence in the deaths of two Bakersfield babies.

"The losses of the young mothers and babies are deeply felt by the families and the community," stated Michele Monserratt-Ramos, Consumer Watchdog's Patient Advocate. "The mothers and the families of the victims want to know how many of their daughters and babies have to die before the Medical Board will revoke his license."

In a May 22nd letter, Consumer Watchdog called on the state's physician licensing board to protect consumers by rejecting the proposed settlement.

"The failure to recommend revocation of Dr. Park's license is made worse by the fact that the Board has another ongoing investigation of the deaths of 23-year-old Demi Dominguez and her baby in Dr. Park's care," wrote Consumer Watchdog. "Ms. Dominguez exhibited clear signs of preeclampsia which were ignored. She was released from the hospital and died at home following a seizure. Her baby Malakhi died 18 hours later. No 23-year old woman should die of treatable preeclampsia today."

Read Consumer Watchdog's letter here:
https://consumerwatchdog.org/sites/default/files/2020-05/Ltr-Medical%20Board-Dr.%20Arthur%20Park%20Stipulation%20Settle%205%2021%202020-FIN.pdf

"I always question why the Medical Board did not take action on Dr. Park's license earlier," stated Tracy Dominguez, mother of Demi Dominguez. "Had the Medical Board acted to protect patients, Demi and Malakhi would be alive today. The Board had the opportunity to save another family from my heartache, but they chose to continue to put our daughters at risk."

Dr. Park's probation does include multiple restrictions on his practice that the Bakersfield public should be aware of, said Consumer Watchdog. However, the settlement and these practice restrictions will not go into effect until June 26, 2020.

The restrictions include:

The Medical Board of California's settlement with Dr. Park can be found by clicking here:
https://www2.mbc.ca.gov/PDL/document.aspx?path=%5cDIDOCS%5c20200528%5cDMRAAAHL3%5c&did=AAAHL200528191527020.DID&licenseType=A&licenseNumber=44597%20#page=1

 "The lives of these young women and babies were valuable," said Michele Monserratt-Ramos. "When will the Medical Board value human life as more important than the rehabilitation of a physician?"

SOURCE Consumer Watchdog


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: